INVESTMENTS IN EQUITY SECURITIES (Details Narrative) $ / shares in Units, € in Millions |
1 Months Ended | 12 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2026
USD ($)
|
Oct. 02, 2025
USD ($)
shares
|
Jul. 01, 2025
USD ($)
shares
|
Jan. 16, 2025
USD ($)
shares
|
Sep. 30, 2024
USD ($)
$ / shares
shares
|
Mar. 31, 2022
USD ($)
shares
|
Jul. 31, 2020
USD ($)
shares
|
Dec. 31, 2021
USD ($)
shares
|
Dec. 31, 2025
USD ($)
|
Oct. 02, 2025
EUR (€)
|
Jul. 01, 2025
EUR (€)
|
Jan. 16, 2025
EUR (€)
|
|
| initial cash investment | $ 14,164,351 | $ 14,626,858 | ||||||||||
| Equity investment | $ 9,000,000.0 | € 8.0 | ||||||||||
| Long term investments | $ 14,164,351 | $ 14,626,858 | ||||||||||
| ChemoMouthpiece, LLC [Member] | ||||||||||||
| Ownership percentage | 6.64% | |||||||||||
| ChemoMouthpiece, LLC [Member] | Investor [Member] | ||||||||||||
| Ownership percentage | 6.59% | |||||||||||
| Direct Dermatology Inc. [Member] | ||||||||||||
| Ownership percentage | 8.10% | |||||||||||
| Direct Dermatology Inc. [Member] | Series B-2 Preferred Shares [Member] | ||||||||||||
| Purchase of additional shares | shares | 3,571,429 | 7,142,857 | 3,571,430 | |||||||||
| Value of shares purchased | $ 250,000 | $ 250,000 | ||||||||||
| Long term investments | $ 500,000 | |||||||||||
| Common Units [Member] | ChemoMouthpiece, LLC [Member] | ||||||||||||
| Purchase of additional shares | shares | 100,674.72 | |||||||||||
| Value of shares purchased | $ 5,000,000.0 | |||||||||||
| Share price per unit | $ / shares | $ 49.6649 | |||||||||||
| BMI License Agreement [Member] | ||||||||||||
| initial cash investment | $ 3,100,000 | € 3.0 | ||||||||||
| Convertible loan | $ 1,100,000 | 1.0 | ||||||||||
| Purchase of additional shares | shares | 8,230 | |||||||||||
| Outstanding equity percentage | 12.141% | 12.499% | 9.678% | 6.67% | ||||||||
| Additional contribution | € | € 4.0 | |||||||||||
| Number of exchange of additional ordinary shares | shares | 4,114 | 4,116 | 8,230 | |||||||||
| Equity investment | $ 2,400,000 | $ 2,400,000 | € 2.0 | € 2.0 | ||||||||
| X | ||||||||||
- Definition Additional contribution. No definition available.
|
| X | ||||||||||
- Definition Equity investment. No definition available.
|
| X | ||||||||||
- Definition Number of exchange of additional ordinary shares. No definition available.
|
| X | ||||||||||
- Definition Outstanding equity percentage. No definition available.
|
| X | ||||||||||
- Definition Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per share or per unit amount of equity securities issued. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|